The FDA issued a complete response letter to Takeda Pharmaceutical Co. Ltd. last week regarding new drug applications for alogliptin and fixed-dose combinations of alogliptin and pioglitazone for Type II diabetes, products partnered with Furiex Pharmaceuticals Inc.